Search

Supplemental Material, sj-pdf-1-atl-10.1177_02611929211060264 for A Systematic Review of Published Physiologically based Kinetic Models and an Assessment of their Chemical Space Coverage by Courtney V Thompson, James W Firman, Michael R Goldsmith, Christopher M Grulke, Yu-Mei Tan, Alicia Paini, Peter E Penson, Risa R Sayre, Steven Webb and Judith C Madden in Alternatives to Laboratory Animals

Supplemental Material, sj-pdf-2-atl-10.1177_02611929211060264 for A Systematic Review of Published Physiologically based Kinetic Models and an Assessment of their Chemical Space Coverage by Courtney V Thompson, James W Firman, Michael R Goldsmith, Christopher M Grulke, Yu-Mei Tan, Alicia Paini, Peter E Penson, Risa R Sayre, Steven Webb and Judith C Madden in Alternatives to Laboratory Animals

Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowering drugs, that not only allow for the effective reduction of LDL-C and do not increase the risk of new onset diabetes (NOD), and/or glucose impairment; in the opposite, some of them might effectively improve glucose control. One of the most interesting is pitavastatin, which is now available in Europe, with the best metabolic profile within statins (no risk of NOD, improvement of fasting blood glucose, HOMA-IR, HbA1c), bempedoic acid (with the potential for the reduction of NOD risk), innovative therapies—PCSK9 inhibitors and inclisiran with no DMT2 risk increase, and new forthcoming therapies, including apabetalone and obicetrapib—for the latter one with the possibility of even decreasing the number of patients diagnosed with prediabetes and DMT2. Altogether, nowadays we have possibility to individualize lipid lowering therapy in DMT2 patients and increase the number of patients on LDL-C goal without any risk of new onset diabetes and/or diabetes control worsening, and in consequence to reduce the risk of CVD complications due to progression of atherosclerosis in this patients’ group.